Stock DNA
Pharmaceuticals & Biotechnology
DKK 121,369 Million ()
29.00
NA
3.64%
1.04
24.43%
7.53
Revenue and Profits:
Net Sales:
6,958 Million
(Quarterly Results - Jun 2025)
Net Profit:
805 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
227.05%
0%
227.05%
6 Months
279.15%
0%
279.15%
1 Year
384.54%
0%
384.54%
2 Years
524.95%
0%
524.95%
3 Years
672.87%
0%
672.87%
4 Years
790.73%
0%
790.73%
5 Years
707.22%
0%
707.22%
Coloplast A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.49%
EBIT Growth (5y)
5.43%
EBIT to Interest (avg)
27.35
Debt to EBITDA (avg)
1.46
Net Debt to Equity (avg)
1.34
Sales to Capital Employed (avg)
1.11
Tax Ratio
30.03%
Dividend Payout Ratio
142.56%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
40.03%
ROE (avg)
47.24%
Valuation key factors
Factor
Value
P/E Ratio
29
Industry P/E
Price to Book Value
7.47
EV to EBIT
19.10
EV to EBITDA
16.23
EV to Capital Employed
3.71
EV to Sales
5.23
PEG Ratio
NA
Dividend Yield
3.59%
ROCE (Latest)
19.44%
ROE (Latest)
26.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
6,958.00
6,885.00
1.06%
Operating Profit (PBDIT) excl Other Income
2,232.00
2,185.00
2.15%
Interest
190.00
229.00
-17.03%
Exceptional Items
-67.00
-55.00
-21.82%
Consolidate Net Profit
805.00
1,274.00
-36.81%
Operating Profit Margin (Excl OI)
271.50%
269.70%
0.18%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 1.06% vs 12.72% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -36.81% vs 0.16% in Jun 2024
Annual Results Snapshot (Consolidated) - Sep'24
Sep'24
Sep'23
Change(%)
Net Sales
27,030.00
24,500.00
10.33%
Operating Profit (PBDIT) excl Other Income
8,700.00
7,858.00
10.72%
Interest
882.00
719.00
22.67%
Exceptional Items
-89.00
-33.00
-169.70%
Consolidate Net Profit
5,052.00
4,783.00
5.62%
Operating Profit Margin (Excl OI)
274.10%
277.10%
-0.30%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2024 is 10.33% vs 8.51% in Sep 2023
Consolidated Net Profit
YoY Growth in year ended Sep 2024 is 5.62% vs 1.64% in Sep 2023
About Coloplast A/S 
Coloplast A/S
Pharmaceuticals & Biotechnology
Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.
Company Coordinates 
Company Details
Holtedam 1-3 , HUMLEBAEK None : 3050
Registrar Details






